NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) to Present Bria-IMT Clinical Data at San Antonio Breast Cancer Symposium

November 19, 2018 12:17:50

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatment options for cancer, this morning announced that its Bria-IMT will be featured in a poster session during this year’s San Antonio Breast Cancer Symposium (“SABCS”), to be held December 4-8, 2018, in San Antonio, Texas. The poster highlights data on Bria-IMT’s use as a monotherapy demonstrating positive proof-of-concept, as well as an initial safety and tolerability assessment for its use in combination with pembrolizumab [KEYTRUDA – manufactured by Merck & Co., Inc. (NYSE: MRK)] for advanced breast cancer. Thomas Jefferson University assistant professor of medical oncology and main principal investigator (PI) of the study Saveri Bhattacharya, DO, will present the poster. Copies of the abstract and the poster will be available on the company’s website following the presentation.

“Despite years of research and improved treatments for breast cancer, according to the latest figures by American Cancer Society, over 40,000 people are expected to die of breast cancer in the United States this year, presenting a large unmet medical need,” BriaCell President and CEO Dr. Bill Williams stated in the news release. “Several challenges need to be addressed, including improving efficacy, safety, and containing the cost of care. At BriaCell, we have been working to resolve all these issues. Bria-IMT has demonstrated positive proof-of-concept in advanced breast cancer, and we will delve into these data in San Antonio.  We have firm grounds to believe the anti-tumor effects of Bria-IMT can be greatly improved by combination with KEYTRUDA. We are excited with the early clinical findings of this novel treatment approach and look forward to presenting our data.”

To view the full press release, visit

About BriaCell

BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at

More from NetworkNewsBreaks

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office